FGFR1 and prostate cancer: CYP2E1 is involved in xenobiotic detoxification but is also a driver of ROS production [12]; FGFR1 is linked to proliferation and treatment resistance [13]; and GSTM2 has been identified in antioxidant defense and has been associated with resilience to treatment and OS-induced stress in prostate cancer [14].